AST Equimucin- Acetylcysteine for horses
Name of the veterinary medicinal product
Equimucin® 2g, oral powder
Qualitative and quantitative composition
1 sachet of 6 g oral powder contains:
Active substance: Acetylcysteine 2000 mg
Excipients: Sucrose (Saccharose)
Indications for use, specifying the target species
Reduction of viscosity of the tracheobronchial secretion in the supportive mucolytic treatment of chronic broncho-pulmonary diseases accompanied by abnormal secretion and mucostasis.
Do not administer in combination with anti-tussives, this may lead to a hazardous build up of secretion due to the restricted cough reflex.
Special warnings for each target species
Special precautions for use
Special precautions for use in animals
- Equimucin® 2g, oral powder should not be used in horses suspected of suffering from gastric ulceration.
- As acetylcysteine is metabolised to sulphur containing products, use cautiously in horses known to be suffering from liver disease.
Special precautions to be taken by the person administering the medicinal products to animals
Persons should wear gloves during administration.
Adverses reactions (frequency and seriousness)
Hypersensitivity to acetylcysteine may occur.
Should undesirable effects occur, withdraw Equimucin® 2g, oral powder and treat symptomatically.
Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic effect. Safety of Equimucin® 2g, oral powder has not been established during pregnancy and lactation. Use only accordingly to the risk/benefit assessment by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
- Acetylcysteine must not be combined with other medicinal products as incompatibilities may occur.
- Reports of inactivation of beta lactam antibiotics (penicillins and cephalosporins) and tetracyclines have so far referred to in-vitro tests in which the substances were directly mixed. An interval of at least 2 hours should be allowed to elapse before administering these antibiotics (this does not apply to doxycycline).
- Acetylcysteine is compatible with potentiated sulfonamides and all current bronchodilators and can be administered concomitantly.
- Concomitant administration with antitussives may lead to a hazardous build-up of secretion due to the restricted cough reflex. Combined treatment of Equimucin® 2g, oral powder and antitussives should therefore be avoided.
Amount(s) to be administered and administration route
10 mg/kg bw acetylcysteine twice daily (total daily dose of 20 mg/kg bw), during 20 days.
[kg body weight] Recommended morning dose[Sachets Equimucin® 2g, oral powder] Recommended evening dose[Sachets Equimucin® 2g, oral powder]
Up to 200 kg 1 sachet 1 sachet
Up to 400 kg 2 sachets 2 sachets
Up to 600 kg 3 sachets 3 sachets
Overdose (symptoms, emergency procedures, antidotes), if necessary
Daily oral administration of 3 times the recommended treatment dose for a period of 4 weeks to horses was tolerated without undesirable effects.
- Meat and offal: zero days
- Milk*: zero days, to be considered in countries were horse milk is used for human consumption.
Pharmacotherapeutic group: Mucolytics
Acetylcysteine can reduce the viscosity of bronchial mucus through reductive breaking of the disulfide bridges of mucopolysaccharides and trigger a mucolytic effect following oral administration.
According to in vitro observations, acetylcysteine exerted protective effects due to the direct detoxification of toxins in the respiratory tract through reduction (e.g. of oxidising substances) and conjugation (e.g. formaldehyde). Free radicals can be bound and thus inactivated by the reactive SH group. These protective properties are not demonstrated in vivo at present.
Following oral administration to man, acetylcysteine is rapidly and virtually completely absorbed and metabolised in the liver into the endogenous amino acid, cysteine, the pharmacologically active metabolite, as well as diacetylcysteine, cystine and other combined disulfides and inorganic sulfate.
The bioavailability in man of orally administered acetylcysteine is very low due to the high first-pass effect (approximately 10%). Pharmakokinetic data in horses are not available at present.
In laboratory animals acetylcysteine and its metabolites are excreted almost exclusively in the form of inactive metabolites (inorganic sulfates, diacetylcysteine) via the kidneys. Inorganic sulfate is the principal excretion product in urine. Small quantities of unchanged acetylcysteine are always present in the urine as acetylcysteine is a physiological intermediate.
Acetylcysteine can lead to the in-vitro inactivation of antibiotics
(see also section 5.7).
Special precautions for storage
Do not store above 25°C.
Nature and contents of immediate packaging
Sachet (LDPE/aluminium/LDPE/paper) with sealed edges containing
6 g oral powder.
Cardboard box of 100 sachets, each containing 6 g oral powder.
Cardboard box of 200 sachets, each containing 6 g oral powder.
Cardboard box of 500 sachets, each containing 6 g oral powder.
Special precautions for the disposal of unused product or waste materials derived from the use of such products, if appropriate
Any unused product or waste material should be disposed of in accordance with national requirements.
Equimucin should be administered in consultation with your Vet